Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis

[1]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[2]  H. Hagan,et al.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs , 2017, The Cochrane database of systematic reviews.

[3]  J. Montaner,et al.  HIV and the criminalisation of drug use among people who inject drugs: a systematic review. , 2017, The lancet. HIV.

[4]  A. Pharris,et al.  Rapid Decline in HIV Incidence Among Persons Who Inject Drugs During a Fast-Track Combination Prevention Program After an HIV Outbreak in Athens , 2017, The Journal of infectious diseases.

[5]  P. Hayes,et al.  Modelling the impact of incarceration and prison‐based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland , 2017, Addiction.

[6]  G. Lauer,et al.  Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  T. Vos,et al.  Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. , 2016, The Lancet. Infectious diseases.

[8]  Y. Kestens,et al.  The role of living context in prescription opioid injection and the associated risk of hepatitis C infection. , 2016, Addiction.

[9]  F. Altice,et al.  The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia , 2016, The Lancet.

[10]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[11]  B. Moazen,et al.  Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners , 2016, The Lancet.

[12]  M. Mckee,et al.  Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees , 2016, The Lancet.

[13]  P. Nguyen,et al.  Impact of length of injecting career on HIV incidence among people who inject drugs. , 2016, Addictive behaviors.

[14]  C. Beyrer,et al.  Public health and international drug policy , 2016, The Lancet.

[15]  Heino Stöver,et al.  Prison-based needle and syringe programmes (PNSP) – Still highly controversial after all these years , 2016 .

[16]  J. Montaner,et al.  Sex work and HIV incidence among people who inject drugs , 2016, AIDS.

[17]  M. Medina-Mora,et al.  Risk of violence in drug rehabilitation centers: perceptions of people who inject drugs in Tijuana, Mexico , 2016, Substance Abuse Treatment, Prevention, and Policy.

[18]  J. Montaner,et al.  Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study. , 2015, The lancet. HIV.

[19]  P. Nguyen,et al.  Impact of incarceration on rates of methadone use in a community recruited cohort of injection drug users. , 2015, Addictive behaviors.

[20]  D. Vlahov,et al.  Incarceration and injection drug use in Baltimore, Maryland. , 2015, Addiction.

[21]  C. Toro,et al.  High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes , 2015, Journal of Epidemiology & Community Health.

[22]  Marie-Ève Turcotte,et al.  P1254 : Hepatitis C spontaneous clearance may induce partial protection against reinfection among persons who inject drugs: Results from a cohort study , 2015 .

[23]  M. Boily,et al.  Influence of different drugs on HIV risk in people who inject: systematic review and meta-analysis. , 2015, Addiction.

[24]  Elizabeth L. Ogburn,et al.  High HIV burden among people who inject drugs in 15 Indian cities , 2015, AIDS.

[25]  J. Hahn,et al.  Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. , 2014, JAMA internal medicine.

[26]  F. Luciani,et al.  A prospective study of hepatitis C incidence in Australian prisoners. , 2014, Addiction.

[27]  V. Hope,et al.  Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey , 2014, Epidemiology and Infection.

[28]  S. Hutchinson,et al.  Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions , 2014, PloS one.

[29]  J. Mcnicholl,et al.  Risk Behaviors and Risk Factors for HIV Infection among Participants in the Bangkok Tenofovir Study, an HIV Pre-Exposure Prophylaxis Trial among People Who Inject Drugs , 2014, PloS one.

[30]  J. Parry,et al.  Factors associated with recent symptoms of an injection site infection or injury among people who inject drugs in three English cities. , 2014, The International journal on drug policy.

[31]  M. Hellard,et al.  Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. , 2014, International journal of epidemiology.

[32]  J. Kaldor,et al.  Extremely low and sustained HIV incidence among people who inject drugs in a setting of harm reduction , 2014, AIDS.

[33]  M. Hellard,et al.  Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. , 2014, The International journal on drug policy.

[34]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[35]  J. Kaldor,et al.  Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. , 2013, American journal of public health.

[36]  M. Hickman,et al.  Low incidence of hepatitis C virus among prisoners in Scotland. , 2013, Addiction.

[37]  C. Aitken,et al.  Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results , 2013, Harm Reduction Journal.

[38]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[39]  Gail M. Williams,et al.  Systematic review of record linkage studies of mortality in ex-prisoners: why (good) methods matter. , 2013, Addiction.

[40]  J. Havens,et al.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. , 2013, American journal of public health.

[41]  L. Topp,et al.  Housing Instability among People Who Inject Drugs: Results from the Australian Needle and Syringe Program Survey , 2013, Journal of Urban Health.

[42]  P Vickerman,et al.  Respondent driven sampling and community structure in a population of injecting drug users, Bristol, UK. , 2012, Drug and alcohol dependence.

[43]  R. Garfein,et al.  HIV Infection Risk among Injection Drug Users in a Methadone Maintenance Treatment Program, Taipei, Taiwan 2007–2010 , 2012, The American journal of drug and alcohol abuse.

[44]  P. Vickerman,et al.  Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[45]  S. Hutchinson,et al.  Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. , 2012, The International journal on drug policy.

[46]  M. Schechter,et al.  The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities , 2012, BMC Public Health.

[47]  J. Bruneau,et al.  The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. , 2012, Addiction.

[48]  J. Steiner,et al.  Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors , 2012, Addiction Science & Clinical Practice.

[49]  L. Møller,et al.  The effectiveness of opioid maintenance treatment in prison settings: a systematic review. , 2012, Addiction.

[50]  Barbara Toson,et al.  Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. , 2012, Addiction.

[51]  A. Widell,et al.  Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program , 2011, Journal of viral hepatitis.

[52]  J. Parry,et al.  The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.

[53]  M. Alary,et al.  Temporal changes in risk factors associated with HIV seroconversion among injection drug users in eastern central Canada , 2011, AIDS.

[54]  M. Abrahamowicz,et al.  Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in montreal, Canada: a 16-year longitudinal study. , 2011, American journal of epidemiology.

[55]  J. Parry,et al.  Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots , 2011, Journal of viral hepatitis.

[56]  D. Vlahov,et al.  Changes in blood-borne infection risk among injection drug users. , 2011, The Journal of infectious diseases.

[57]  M. Farrell,et al.  Meta-analysis of drug-related deaths soon after release from prison , 2010, Addiction.

[58]  J. Tappero,et al.  Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003. , 2010, The International journal on drug policy.

[59]  H. Hagan,et al.  Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. , 2010, The Journal of infectious diseases.

[60]  J. Parry,et al.  Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size , 2009, Epidemiology and Infection.

[61]  J. Tappero,et al.  Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. , 2009, Addiction.

[62]  J. Montaner,et al.  Incidence and determinants of initiation into cocaine injection and correlates of frequent cocaine injectors. , 2009, Drug and alcohol dependence.

[63]  Margaret Hellard,et al.  High incidence of hepatitis C virus reinfection in a cohort of injecting drug users , 2008, Hepatology.

[64]  M. Faruque,et al.  Prevalence of Infections, HIV Risk Behaviors and Factors Associated with HIV Infection Among Male Injecting Drug Users Attending a Needle/Syringe Exchange Program in Dhaka, Bangladesh , 2008, Substance use & misuse.

[65]  Kimberly C. Brouwer,et al.  Individual, Social, and Environmental Influences Associated With HIV Infection Among Injection Drug Users in Tijuana, Mexico , 2008, Journal of acquired immune deficiency syndromes.

[66]  K. Nelson,et al.  Not All Injection Drug Users Are Created Equal: Heterogeneity of HIV, Hepatitis C Virus, and Hepatitis B Virus Infection in Georgia , 2008, Substance use & misuse.

[67]  J. Kaldor,et al.  High incidence of hepatitis C virus reinfection within a cohort of injecting drug users , 2007, Journal of viral hepatitis.

[68]  D. Vlahov,et al.  HIV Incidence Among Injection Drug Users in Baltimore, Maryland (1988-2004) , 2006, Journal of acquired immune deficiency syndromes.

[69]  Tania B. Huedo-Medina,et al.  Assessing heterogeneity in meta-analysis: Q statistic or I2 index? , 2006, Psychological methods.

[70]  J. Montaner,et al.  Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study , 2006, Harm reduction journal.

[71]  C. del Rio,et al.  Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. , 2006, Drug and alcohol dependence.

[72]  C. Boileau,et al.  A Prognostic Model for HIV Seroconversion Among Injection Drug Users as a Tool for Stratification in Clinical Trials , 2005, Journal of acquired immune deficiency syndromes.

[73]  J. Montaner,et al.  Recent Incarceration Independently Associated with Syringe Sharing by Injection Drug Users , 2005, Public health reports.

[74]  J. Desenclos,et al.  Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France , 2004, Epidemiology and Infection.

[75]  J. Tappero,et al.  HIV type 1 incidence estimates by detection of recent infection from a cross-sectional sampling of injection drug users in Bangkok: use of the IgG capture BED enzyme immunoassay. , 2003, AIDS research and human retroviruses.

[76]  M. Schechter,et al.  Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic , 2003, AIDS.

[77]  J. Barry,et al.  Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin , 2003, Journal of epidemiology and community health.

[78]  R. Hogg,et al.  Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[79]  M. Busch,et al.  Hepatitis C virus seroconversion among young injection drug users: relationships and risks. , 2002, The Journal of infectious diseases.

[80]  D. Vlahov,et al.  Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. , 2002, American journal of epidemiology.

[81]  M. Schechter,et al.  Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[82]  M. Hudgens,et al.  Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. , 2002, American journal of epidemiology.

[83]  D. D. Des Jarlais,et al.  Incarceration and Risk for HIV Infection Among Injection Drug Users in Bangkok , 2002, Journal of acquired immune deficiency syndromes.

[84]  M. Schechter,et al.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection , 2022 .

[85]  D. Vlahov,et al.  Sex differences in risk factors for hiv seroconversion among injection drug users: a 10-year perspective. , 2001, Archives of internal medicine.

[86]  J. Esparza,et al.  Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand , 2001, AIDS.

[87]  D. Harte,et al.  Cumulative incidence of hepatitis C seroconversion in a cohort of seronegative injecting drug users. , 2000, The New Zealand medical journal.

[88]  J. Zhang,et al.  What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. , 1998, JAMA.

[89]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[90]  M. Anglin,et al.  HIV incidence among injection drug users. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.